Shanghai HEP Pharmaceatical Co., Ltd.   Report issue

For profit Phase 2
Founded: Shanghai China (2005)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2015
NCT02612506
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Shanghai HEP Pharmaceatical Co., Ltd. | Shanghai HEP Pharmaceutical Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4